Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
Oncology Department, Hospital del Mar, Barcelona, Spain.
Lung Cancer. 2015 Nov;90(2):302-6. doi: 10.1016/j.lungcan.2015.09.023. Epub 2015 Sep 26.
Small cell lung cancer (SCLC) is a highly lethal disease due to its chemorefractory nature after initial treatment. Angiogenesis plays an important role in tumor growth, metastasis and chemoresistance. We hypothesized that angiogenesis could predict chemoresistance in SCLC patients and be potentially a therapeutic target in this disease.
Serum samples from forty-three SCLC patients were prospectively obtained at diagnosis, response evaluation and progression. Angiogenesis-related cytokines (Angiopoietin-2, VEGF-A, C and D) were simultaneously quantified by Luminex Technology. Clinical data were prospectively recorder.
Significantly higher concentration of angiogenesis-related cytokines were found in SCLC patients at diagnosis compared to healthy volunteers. High baseline serum concentration of Angiopoietin-2 (sAngiopoietin-2) were associated with a worse overall survival (p=0.006) and remained independently associated with survival in the multivariate analysis (p=0.008). In addition, sAngiopoietin-2 significantly increased at progression when compared to baseline.
These data provide novel evidence on a role of sAngiopoietin-2 in the adverse clinical behavior of SCLC and could be a potential therapeutic target in this disease.
小细胞肺癌（SCLC）由于初始治疗后的化学抵抗性质，是一种高度致命的疾病。血管生成在肿瘤生长、转移和化学抵抗中起重要作用。我们假设血管生成可以预测 SCLC 患者的化学抵抗性，并可能成为该疾病的潜在治疗靶点。
前瞻性地在诊断、反应评估和进展时从 43 名 SCLC 患者中获得血清样本。通过 Luminex 技术同时定量检测与血管生成相关的细胞因子（血管生成素-2、VEGF-A、C 和 D）。前瞻性地记录临床数据。
与健康志愿者相比，SCLC 患者在诊断时发现血管生成相关细胞因子的浓度明显更高。高基线血清浓度的血管生成素-2（sAngiopoietin-2）与总生存期较差相关（p=0.006），并在多变量分析中仍然与生存相关（p=0.008）。此外，与基线相比，sAngiopoietin-2 在进展时显著增加。
这些数据为 sAngiopoietin-2 在 SCLC 的不良临床行为中的作用提供了新的证据，并可能成为该疾病的潜在治疗靶点。
